แนวคิดหลัก
Topical ruxolitinib shows efficacy and safety in dermatological conditions.
สถิติ
Topical 1.5% RUX cream FDA approved for AD in September 2021 and nonsegmental vitiligo in July 2022.
คำพูด
"Topical ruxolitinib formulations show improvement in atopic dermatitis, vitiligo, psoriasis, and lichen planus."
"Favorable safety profile and higher tolerability of topical ruxolitinib compared to oral JAK-inhibitors."